Influence of Gemcitabine Treatment on Immunological and Serological Profile in Patients With Pancreatic Cancer

Blood Transfusion Centre of Slovenia

Overview

Observational study of influence of gemcitabine treatment on serological and immunological status and gene expression profile in patients with pancreatic tubular carcinoma after tumor resection.

Study Type

OBSERVATIONAL

Conditions

Pancreatic Tubular Adenocarcinoma

Interventions

ObservationOTHER

Eligibility

Sex: ALLMin age: 30 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ECOG performance status 0-2 at the time of inclusion * Following R0 or R1 pancreatic tubular adenocarcinoma resection Exclusion Criteria: * Pregnancy * Serious comorbidity

Locations (1)

University Medical Centre Ljubljana; Department for Gastroenterology

Ljubljana, Ljubljana, Slovenia

RECRUITING

Central Contacts

Borut Stabuc, MD, PhD

CONTACT

+386 1 522 22 10 borut.stabuc@kclj.si

Lojze Smid, MD

CONTACT

lojze.smid.jr@mf.uni-lj.si

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.